Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Haleon PLC ( (GB:HLN) ) just unveiled an update.
Haleon PLC announced the purchase of 881,993 ordinary shares for cancellation as part of its share buyback program. This transaction impacts the company’s share capital, reducing the number of shares with voting rights and potentially affecting shareholder interests under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Neutral.
Haleon PLC’s overall stock score is driven by strong financial performance and positive earnings call outlook, supported by strategic growth initiatives and innovation. However, technical analysis and valuation indicate some caution, with bearish trends and moderate income returns. The company’s resilience in challenging markets and commitment to shareholder returns through buybacks and dividends bolster confidence.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a range of products across six major categories: Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The company is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 23,069,477
Technical Sentiment Signal: Hold
Current Market Cap: £32.99B
For a thorough assessment of HLN stock, go to TipRanks’ Stock Analysis page.